Immunai

Company Overview

Snapshot

Founded in January 2019 by Noam Solomon, Luis Voloch, and Ansuman Satpathy, Immunai operates with 51–200 employees. The company has raised $295M across 3 funding rounds from 14 investors. In October 2021, Immunai announced a $215M Series B round, highlighting the maturation of its immune cell atlas.

Business overview

Immunai is a Health Tech & Life Sciences company focused on developing a proprietary dataset of multi-omic, immune-centric peripheral tissue analyses. The company's core technology leverages advanced analytics and a data-visualization interface, powered by artificial intelligence, machine learning, and deep learning, to enable researchers to comprehensively view and interrogate data. This platform helps derive novel conclusions on the underlying mechanisms of disease and is currently applied to develop and refine cell therapies, such as for neuroblastoma in collaboration with the Baylor College of Medicine. Immunai serves the healthcare and life sciences industries, including laboratories, providers, and pharmaceutical companies, operating within the Digital Healthcare and Pharma & Medical Biotechnology sectors.

Strategic signal

In May 2026, Immunai's immune-system modeling platform extended its support for oncology drug development through 2027. This continued engagement signals strong validation of Immunai's AI-driven approach in critical therapeutic areas, demonstrating its long-term strategic value to pharmaceutical partners and its sustained impact on advancing oncology research and development.

Company Intelligence Q&A

What was a significant recent partnership for Immunai?

In May 2026, Immunai's immune-system modeling platform continued its support for oncology drug development through 2027, indicating an ongoing and strengthened collaboration in the field.

What was the outcome of Immunai's Series B funding round?

In October 2021, Immunai announced a Series B funding round that contributed to its total capital raised of $295 million. Koch Disruptive Technologies was a lead investor in this round.

What was a key strategic acquisition by Immunai?

In August 2021, Immunai acquired Nebion, expanding its capabilities and strengthening its position in the market.

What is Immunai's collaboration with Teva focused on?

In November 2024, Immunai and Teva launched a multi-year AI collaboration aimed at enhancing precision in immunology and oncology trials by utilizing Immunai’s immune system mapping tools.

What was another strategic acquisition made by Immunai?

In March 2021, Immunai acquired Dropprint Genomics, which expanded its target discovery capabilities and strengthened its leadership team with experts in immunology.